The low frequency of mutant (mut)p53 in melanoma has been mostly attributed to the inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) locus, encoding p16INK4A and p14ARF, which potentially renders the p53 mutation unwarranted. This evidence concerns the gene TP53 and melanoma.